Novel hepatotrophic prodrugs of the antiviral nucleoside 9-(2-phosphonylmethoxyethyl)adenine with improved pharmacokinetics and antiviral activity

FASEB Journal

Volumn 14, Issue 12, 2000, Pages 1784-1792

  Biessen, E A L ^a   Valentijn, A R P M ^a   De Vrueh, R L A ^a   Van De Bilt, E ^a   Sliedregt, L A J M ^a   Prince, P ^a   Bijsterbosch, M K ^a   Van Boom, J H ^a   Van Der Marel, G A ^a   Abrahams, P J ^a   Van Berkel, T J G ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Asialoglycoprotein; Drug targeting; HBV; HSV 1; Liver

Indexed keywords

ANTIVIRUS AGENT; ASIALOGLYCOPROTEIN RECEPTOR; GLYCOSIDE; NUCLEOSIDE 9 (2 PHOSPHONYLMETHYOXYETHYL)ADENINE; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG TRANSPORT; DRUG UPTAKE; HEPATITIS B; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALIA; HEPATITIS B VIRUS; HUMAN HERPESVIRUS 1;

EID: 0033823056     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.99-0887com     Document Type: Article

References (49)

1. Effect of alpha-interferon treatment in patients with hepatitis B and antigen-positive chronic hepatitis B. A meta-analysis
2. The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep)
3. Review: Hepatitis B and liver transplantation
4. New therapies for chronic hepatitis B
5. A preliminary trial of lamivudine for chronic hepatitis B infection
6. Lamivudine therapy for chronic hepatitis B: A six month randomized dose ranging study
7. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine
8. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns
9. Lamivudine resistance in chronic hepatitis B
10. HPMPC (cidovir), PMEA (adefovir), and related acyclic nucleoside phosphonate analogues: A review of their pharmacology and clinical potential in the treatment of viral infections
11. New nucleoside analogues for chronic hepatitis B
12. Pharmacokinetics in mice of the anti retrovirus agent 9 (2 phosphonylmethoxyethyl)adenine
13. 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl] cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivo
14. Antimalarial and toxic effects of the acyclic nucleoside phosphonate (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine in Plasmodium berghei-infected mice
15. Selective liver targeting of antivirals by recombinant chylomicrons: A new therapeutic approach to hepatitis B
16. Specific targeting of a lipophilic prodrug of iododeoxyuridine to parenchymal liver cells using lactosylated reconstituted high density, lipoprotein particles
17. Drug targeting in antiviral chemotherapy. A chemically stable conjugate of 9 beta D arabinofuranosyl adenine 5'-monophosphate with lactosaminated albumin accomplishes a selective delivery of the drug to liver cells
18. Liver targeting of antiviral nucleoside analogues through the asialoglycoprotein receptor
19. Adenine arabinoside monophosphate coupled to lactosaminated human albumin administered for 4 weeks in patients with chronic type B hepatitis decreased viremia without producing significant side effects
20. Coupling of the antiviral drug ara AMP to lactosaminated albumin leads to specific uptake in rat and human hepatocytes
21. Specific targeting of the antiviral drug 5-iodo-2'-deoxyuridine to the parenchymal liver cell using lactosylated poly-L-lysine
22. Inhibition of woodchuck hepatitis virus replication by adenosine arabinoside monophosphate coupled to lactosaminated poly-L-lysine and administered by intramuscular route
23. Conjugation of adenine arabinoside-5'-monophosphate to arabinogalactan: Synthesis, characterization, and antiviral activity
24. Lipoprotein receptors and atherogenic receptor-mediated mechanisms
25. Carbohydrate-specific receptors of the liver
26. Synthesis of cluster galactosides with high affinity for the hepatic asialoglycoprotein receptor
27. Preparation of cluster glycosides and GalNAc that have sub-nanomolar binding affinity toward mammalian hepatic Gal/GalNAc-specific receptors
28. 7, in the mouse
29. Solid-phase synthesis of lysine-based cluster galactosides with high affinity for the asialoglycoprotein receptor
30. Synthesis of 9 (2 phosphonylmethoxymethyl)adenine and related compounds
31. Synthesis of a lipophilic prodrug of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) and its incorporation into a hepatocyte-specific lipidic carrier
32. The metabolism of very-low density-lipoproteins. I. Preliminary in-vitro and in-vivo observations
33. Different fate in vivo of oxidatively modified LDL and acetylated LDL in rats Recognition by various scavenger receptors on Kupffer and endothelial liver cells
34. Targeted delivery of antisense oligonucleotides to parenchymal liver cells in vivo
35. Evans blue space in tissues of the rat
36. In vivo and in vitro uptake and degradation of acetylated low-density-lipoprotein by rat liver endothelial. Kupffer, and parenchymal cells
37. Enhanced reactivation and enhanced mutagenesis of herpes simplex virus in normal human and xeroderma pigmentosum cells
38. The interaction in vivo of transferrin and asialo-transferrin with liver cells
39. Dynamic measurements of the acute and chronic effects of lysosomotropic agents on hepatocyte lysosomal pH using flow cytometry
40. Antiviral agents - Characteristic activity spectrum depending on the molecular target with which they interact
41. Antiviral agents in hepatitis B virus transfected cell lines: Inhibitory and cytotoxic effect related to time of treatment
42. Asialoglycoprotein receptor in human isolated hepatocytes from normal liver and its apparent increase in liver with histological alterations
43. Abnormal surface distribution of the human asialoglycoprotein receptor in cirrhosis
44. Reactivity and mechanism of hydrolysis of phosphoamides
45. Cellular uptake of phosphonylmethoxyalkyl purine derivatizes
46. Transport of 9-(2-phosphonylmethoxyethyl)adenine across plasma membrane of HeLa S3 cells is protein mediated
47. Reactions of 5'-H-phosphonates, 5'-F-phosphates, and 5'-phosphates of modified thymidines in human blood plasma
48. Herpes simplex virus-specified DNA polymerase is the target for the antiviral action of 9-(2-phosphonylmethoxyethyl)adenine
49. Drug targeting: Anti-HSV-1 activity of mannosylated polymer-bound 9-(2-phosphonylmethoxyethyl)adenine